SEARCH

SEARCH BY CITATION

Keywords:

  • bispecific antibodies;
  • chorioallantois membrane;
  • head and neck squamous cell carcinoma;
  • immunotherapy

Abstract

Background.

The trifunctional bispecific antibody Removab (tbAB) bridges and activates CD3 positive T cells to EpCAM on carcinoma cells and simultaneously binds to an accessory immune-cell inducing tumor cell lysis. tbAB-induced tumor cytotoxicity was assessed in an autologous human ex vivo system.

Methods.

One hundred forty tumor samples and autologous peripheral blood mononuclear cells from a total of 36 patients with head and neck squamous cell carcinomas (HNSCCs) were incubated on a chicken embryo chorioallantois membrane with Removab. Tumor cells coincubated with cisplatin or cell culture medium served as positive and negative controls. Tumor cell lysis was assessed by acridine orange staining or by fluorescence-activated cell sorting of propidium iodide–marked cells after 24 and 48 hours (T24/T48) coincubation.

Results.

Coincubation of HNSCC cells with tbAB and autologous peripheral blood mononuclear cells resulted in a 49% ± 6% decrease of viable cells at T24 (p < .005) and in a decrease of 56% ± 8% at T48 (p < .005) compared with the control. The tumor cytotoxicity was similar to that of cisplatin (49% ± 7% decrease at T24 and 49% ± 8% at T48).

Conclusion.

In an autologous human ex vivo system, the tbAB-induced tumor cell lysis was comparable to that by cisplatin. © 2005 Wiley Periodicals, Inc. Head Neck27: XXX–XXX, 2005